Realcan Pharmaceutical Group Past Earnings Performance
Past criteria checks 1/6
Realcan Pharmaceutical Group's earnings have been declining at an average annual rate of -30.4%, while the Healthcare industry saw earnings growing at 4.2% annually. Revenues have been declining at an average rate of 29.9% per year. Realcan Pharmaceutical Group's return on equity is 0.4%, and it has net margins of 0.2%.
Key information
-30.4%
Earnings growth rate
-30.7%
EPS growth rate
Healthcare Industry Growth | 7.0% |
Revenue growth rate | -29.9% |
Return on equity | 0.4% |
Net Margin | 0.2% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Realcan Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 7,980 | 14 | 815 | 15 |
31 Dec 23 | 8,034 | 20 | 846 | 15 |
30 Sep 23 | 7,520 | -1,873 | 894 | 22 |
30 Jun 23 | 8,840 | -1,859 | 1,263 | 22 |
31 Mar 23 | 10,291 | -1,852 | 1,394 | 21 |
01 Jan 23 | 12,311 | -1,831 | 1,662 | 23 |
30 Sep 22 | 14,321 | 67 | 1,973 | 15 |
30 Jun 22 | 15,900 | 75 | 2,251 | 15 |
31 Mar 22 | 19,389 | 92 | 2,477 | 14 |
01 Jan 22 | 21,060 | 131 | 2,826 | 12 |
30 Sep 21 | 24,851 | 138 | 3,110 | 8 |
30 Jun 21 | 27,244 | 223 | 3,288 | 7 |
31 Mar 21 | 27,235 | 249 | 3,411 | 8 |
31 Dec 20 | 27,234 | 261 | 3,324 | 9 |
30 Sep 20 | 28,333 | -1,257 | 3,367 | 14 |
30 Jun 20 | 30,002 | -1,157 | 3,515 | 12 |
31 Mar 20 | 32,280 | -1,024 | 3,738 | 10 |
31 Dec 19 | 35,259 | -928 | 3,992 | 7 |
30 Sep 19 | 36,307 | 516 | 4,044 | 0 |
30 Jun 19 | 36,368 | 574 | 3,870 | 0 |
31 Mar 19 | 35,531 | 681 | 3,742 | 0 |
31 Dec 18 | 33,919 | 771 | 3,515 | 0 |
30 Sep 18 | 31,196 | 1,119 | 3,098 | 0 |
30 Jun 18 | 28,408 | 1,074 | 2,935 | 0 |
31 Mar 18 | 25,444 | 996 | 2,376 | 0 |
31 Dec 17 | 23,294 | 1,008 | 2,120 | 0 |
30 Sep 17 | 21,381 | 941 | 2,139 | 0 |
30 Jun 17 | 19,094 | 888 | 1,662 | 0 |
31 Mar 17 | 17,355 | 797 | 1,670 | 0 |
31 Dec 16 | 15,619 | 591 | 1,404 | 0 |
30 Sep 16 | 13,602 | 442 | 1,152 | 0 |
30 Jun 16 | 12,167 | 350 | 953 | 0 |
31 Mar 16 | 10,797 | 270 | 779 | 0 |
31 Dec 15 | 9,750 | 236 | 654 | 0 |
30 Sep 15 | 9,222 | 218 | 557 | 0 |
30 Jun 15 | 8,705 | 205 | 480 | 0 |
31 Mar 15 | 8,241 | 192 | 409 | 0 |
31 Dec 14 | 7,786 | 181 | 370 | 0 |
30 Sep 14 | 7,127 | 173 | 303 | 0 |
30 Jun 14 | 6,695 | 162 | 272 | 0 |
31 Mar 14 | 6,322 | 153 | 245 | 0 |
31 Dec 13 | 5,926 | 144 | 232 | 0 |
30 Sep 13 | 5,640 | 133 | 226 | 0 |
30 Jun 13 | 5,319 | 125 | 203 | 0 |
Quality Earnings: 002589 has a large one-off loss of CN¥245.5M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 002589 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002589's earnings have declined by 30.4% per year over the past 5 years.
Accelerating Growth: 002589 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 002589 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (-1%).
Return on Equity
High ROE: 002589's Return on Equity (0.4%) is considered low.